EP-1380: Primary focal prostate radiotherapy: do all patients really need whole-prostate irradiation?

Do all patients with newly diagnosed prostate cancer need staging radionuclide bone scan? A retrospective study.

PURPOSE Define a group of patients with newly diagnosed prostate cancer, whose risk of bone metastasis is low enough to omit a bone scan staging study. MATERIALS AND METHODS From 2003 to 2009, the medical records of patients who were newly diagnosed with prostate cancer were retrospectively reviewed. The data collected included: age, digital rectal examination, serum prostate specific antigen...

Do we really need new trials on fulvestrant in prostate cancer?

likely that the case report presented here can plead for a new prospective study on fulvestrant in CRPC. It is interesting to shortly review the major approaches for identifying new drugs with potential activity on hormone receptors in CRPC. The characteristic of CRPC is an overexpression of androgen receptors (AR) associated with different genetic modifications (AR mutation, for instance). One...

Prostate-specific antigen kinetics after hypofractionated stereotactic body radiotherapy for localized prostate cancer

Background: stereotactic body radiotherapy (SBRT) has emerged as an effective treatment for localized prostate cancer. However, prostate-specific antigen (PSA) kinetics after SBRT has not been well characterized. The objective of the current study is to analyze the rate of PSA decline and PSA nadir following hypofractonated SBRT in localized prostate cancer. Materials and Methods: From 2008...

Prostate-specific antigen kinetics after stereotactic body radiotherapy as monotherapy or boost after whole pelvic radiotherapy for localized prostate cancer.

PURPOSE Stereotactic body radiotherapy (SBRT) has emerged as an effective treatment for localized prostate cancer. However, prostate-specific antigen (PSA) kinetics after SBRT has not been well characterized. The purpose of the current study is to assess the kinetics of PSA for low- and intermediate-risk prostate cancer patients treated with SBRT using Cyberknife as both monotherapy and boost a...

Do We Really Need Consultants?